The global central nervous system (CNS) therapeutics market size is expanding due to increase in geriatric population. There are several drugs in pipeline to combat the CNS diseases. There is also a rise in mental health disorders amongst the global population due to increase in stress levels, anxiety, and unhealthy diet.
The central nervous system (CNS) therapeutics market manufacturers are working toward increasing their consumer base by tapping the unexplored geographies of Latin America, Middle East & Africa, and Asia Pacific.
Various awareness campaigns regarding the importance of identifying the symptoms of brain disorders are being conducted, so as to help the patients with earlier diagnosis and treatment.
Central Nervous System (CNS) diseases enclose several infections (encephalitis and meningitis), structural impairment (spinal injury or brain), vascular issues (stroke and various other hemorrhages), functional issues (migraines and epilepsy), and neurodegenerative conditions (Parkinson’s and Alzheimer’s).
Developing therapeutic strategies for CNS disorders is quite challenging as the cells concerned have noticeable diversity, along with complexity of the neural circuits and linked functions, improper tissue generation, and inappropriate understanding of underlying pathological processes.
However, the key participants are conducting exorbitant research on this count and entering into partnerships and collaborations to expedite the process of devising these therapeutics.
For instance, in October 2020, Roche and Dyno Therapeutics announced entering into a collaborative license agreement in order to use the latter’s CapsidMap platform to develop next-generation adeno-associated virus (AAV) vectors for CNS disorders’ gene therapies and liver-directed therapies for Spark Therapeutics’ product portfolio.
| Attribute | Detail |
|---|---|
| Central Nervous System (CNS) Therapeutics Market Drivers |
|
The common neurological disorders in the geriatric population involving brain comprise stroke, Parkinson’s Disease (PD), dementia (Alzheimer’s Disease being a common cause), Normal Pressure Hydrocephalus (NPH), Delirium due to low sodium or hyponatraemia (Dyselectrolytaemia), and Subdural Haematoma (SDH).
As per the National Institutes of Health, 5-55% of individuals aged 55 and above suffer from neurological diseases. It further states that this population is linked with a higher risk of health hazards such as disability, mortality, hospitalization, and institutionalization.
As per the WHO, 1.4 billion people are expected to be categorized as ‘geriatric’ by 2030 and the number is expected to reach 2.1 billion by the year 2050. Continuous increase in geriatric population is thus catalyzing the central nervous system (CNS) therapeutics market development.
Continual influx of new drugs is maintaining the pace of central nervous system (CNS) therapeutics market. For instance, in August 2022, Paladin Labs Inc. received approval from Health Canada for NDS (New Drug Submission) application for carbamate as one of the adjunctive therapies to manage partial-onset seizures in the adults suffering from epilepsy, especially those who are cannot be controlled through conventional course of treatment.
In January 2023, Eisai Co., Ltd., in collaboration with Biogen Inc., received an accelerated approval from the U.S. FDA for lecanemab-irmb (LEQEMBI) 100 mg/ml injection for intravenous use.
It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody that is directed toward aggregated insoluble and soluble forms of amyloid beta (Aβ) to treat Alzheimer’s disease.
In January 2023, Alcyone Therapeutics and Biogen Inc. agreed upon entering into collaboration to license the former’s ThecaFlex DRx System, one of the implanted medical devices designed to subcutaneously administer antisense oligonucleotide (ASO) medicines into intrathecal area.
Biogen intends using this system for improving the patient’s treatment experience as well as accessibility for a wider population contracting disorders such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).
Continuous research regarding new therapeutics as mentioned above is thus accelerating the central nervous system (CNS) therapeutics market growth.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest central nervous system (CNS) therapeutics market analysis, North America dominated the central nervous system medications landscape in 2023 and the status quo is expected to remain the same during the forecast period.
This is attributed to rise in the incidence of individuals in the U.S. suffering from Alzheimer’s dementia. As per the Alzheimer’s Disease Facts and Figures 2023 published by Alzheimer’s Association, close to 6.7 million Americans aged 65 and above were living with Alzheimer’s dementia in 2023 alone.
Furthermore, as per Statistics Canada study published in 2021, 20% of Canadians aged 12 and above mentioned that they needed help with mental health. In August 2022, the National Multiple Sclerosis Society announced that it would invest US$ 19 Mn for launching 40 new multi-year research awards for driving progress toward stoppage of multiple sclerosis.
The companies in central nervous system (CNS) therapeutics market are launching new products followed by speedy approvals from the regulatory authorities to strengthen their position.
For instance, in February 2023, Sage Therapeutics, Inc, along with Biogen, received approval from the U.S. FDA for a NDA (New Drug Application) for zuranolone to treat postpartum depression (PPD) and major depressive disorder (MDD).
The central nervous system (CNS) therapeutics market report highlights Biogen, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Merck & Co. Inc., AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceuticals, and Johnson & Johnson Services, Inc. based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 102.4 Bn |
| Market Forecast (Value) in 2034 | US$ 231.8 Bn |
| Growth Rate (CAGR) | 7.7% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 102.4 Bn in 2023
It is projected to grow at a CAGR of 7.7% from 2024 to 2034
Rise in geriatric population and neurological disorders associated with them and a long funnel of therapeutics
Hospital pharmacies segment accounted for the largest share in 2023
North America was the dominant region in 2023
Biogen, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Merck & Co. Inc., AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceuticals, and Johnson & Johnson Services, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Central Nervous System (CNS) Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Analgesics
6.3.2. Anti-Cholinergic Agents
6.3.3. Anticonvulsants
6.3.4. Sedatives and Hypnotics
6.3.5. Anti-Depressants
6.3.6. Others (Antipsychotics, etc.)
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, by Disease Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Type, 2020-2034
7.3.1. Neurodegenerative Disorders
7.3.1.1. Alzheimer’s Disease
7.3.1.2. Parkinson’s Disease
7.3.1.3. Huntington’s Disease
7.3.1.4. Amyotrophic Lateral Sclerosis
7.3.1.5. Others (Multiple Sclerosis, etc.)
7.3.2. Mental Health
7.3.2.1. Anxiety Disorders
7.3.2.2. Epilepsy
7.3.2.3. Psychotic Disorders
7.3.2.4. Others (Mood Disorders, etc.)
7.3.3. Neurovascular Diseases
7.3.4. CNS Trauma
7.3.5. CNS Cancer
7.3.6. Others (Infectious Disorders, etc.)
7.4. Market Attractiveness Analysis, by Disease Type
8. Global Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2020-2034
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Central Nervous System (CNS) Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2020-2034.
10.3.1. Analgesics
10.3.2. Anti-Cholinergic Agents
10.3.3. Anticonvulsants
10.3.4. Sedatives and Hypnotics
10.3.5. Anti-Depressants
10.3.6. Others (Antipsychotics, etc.)
10.4. Market Value Forecast, by Disease Type, 2020-2034.
10.4.1. Neurodegenerative Disorders
10.4.1.1. Alzheimer’s Disease
10.4.1.2. Parkinson’s Disease
10.4.1.3. Huntington’s Disease
10.4.1.4. Amyotrophic Lateral Sclerosis
10.4.1.5. Others (Multiple Sclerosis, etc.)
10.4.2. Mental Health
10.4.2.1. Anxiety Disorders
10.4.2.2. Epilepsy
10.4.2.3. Psychotic Disorders
10.4.2.4. Others (Mood Disorders, etc.)
10.4.3. Neurovascular Diseases
10.4.4. CNS Trauma
10.4.5. CNS Cancer
10.4.6. Others (Infectious Disorders, etc.)
10.5. Market Value Forecast, by Distribution Channel, 2020-2034.
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Class
10.7.2. By Disease Type
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Central Nervous System (CNS) Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2020-2034
11.3.1. Analgesics
11.3.2. Anti-Cholinergic Agents
11.3.3. Anticonvulsants
11.3.4. Sedatives and Hypnotics
11.3.5. Anti-Depressants
11.3.6. Others (Antipsychotics, etc.)
11.4. Market Value Forecast, by Disease Type, 2020-2034.
11.4.1. Neurodegenerative Disorders
11.4.1.1. Alzheimer’s Disease
11.4.1.2. Parkinson’s Disease
11.4.1.3. Huntington’s Disease
11.4.1.4. Amyotrophic Lateral Sclerosis
11.4.1.5. Others (Multiple Sclerosis, etc.)
11.4.2. Mental Health
11.4.2.1. Anxiety Disorders
11.4.2.2. Epilepsy
11.4.2.3. Psychotic Disorders
11.4.2.4. Others (Mood Disorders, etc.)
11.4.3. Neurovascular Diseases
11.4.4. CNS Trauma
11.4.5. CNS Cancer
11.4.6. Others (Infectious Disorders, etc.)
11.5. Market Value Forecast, by Distribution Channel, 2020-2034.
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Distribution Channel, 2020-2034.
11.6.1. Hospitals
11.6.2. Biopharmaceutical Companies
11.6.3. Research Organizations and Academic Institutes
11.7. Market Value Forecast, by Country/Sub-region, 2020-2034
11.7.1. Germany
11.7.2. U.K.
11.7.3. France
11.7.4. Italy
11.7.5. Spain
11.7.6. Rest of Europe
11.8. Market Attractiveness Analysis
11.8.1. By Drug Class
11.8.2. By Disease Type
11.8.3. By Distribution Channel
11.8.4. By Country/Sub-region
12. Asia Pacific Central Nervous System (CNS) Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2020-2034.
12.3.1. Analgesics
12.3.2. Anti-Cholinergic Agents
12.3.3. Anticonvulsants
12.3.4. Sedatives and Hypnotics
12.3.5. Anti-Depressants
12.3.6. Others (Antipsychotics, etc.)
12.4. Market Value Forecast, by Disease Type, 2020-2034.
12.4.1. Neurodegenerative Disorders
12.4.1.1. Alzheimer’s Disease
12.4.1.2. Parkinson’s Disease
12.4.1.3. Huntington’s Disease
12.4.1.4. Amyotrophic Lateral Sclerosis
12.4.1.5. Others (Multiple Sclerosis, etc.)
12.4.2. Mental Health
12.4.2.1. Anxiety Disorders
12.4.2.2. Epilepsy
12.4.2.3. Psychotic Disorders
12.4.2.4. Others (Mood Disorders, etc.)
12.4.3. Neurovascular Diseases
12.4.4. CNS Trauma
12.4.5. CNS Cancer
12.4.6. Others (Infectious Disorders, etc.)
12.5. Market Value Forecast, by Distribution Channel, 2020-2034.
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Distribution Channel, 2020-2034.
12.6.1. Hospitals
12.6.2. Biopharmaceutical Companies
12.6.3. Research Organizations and Academic Institutes
12.7. Market Value Forecast, by Country/Sub-region, 2020-2034
12.7.1. China
12.7.2. Japan
12.7.3. India
12.7.4. Australia & New Zealand
12.7.5. Rest of Asia Pacific
12.8. Market Attractiveness Analysis
12.8.1. By Drug Class
12.8.2. By Disease Type
12.8.3. By Distribution Channel
12.8.4. By Country/Sub-region
13. Latin America Central Nervous System (CNS) Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2020-2034
13.3.1. Analgesics
13.3.2. Anti-Cholinergic Agents
13.3.3. Anticonvulsants
13.3.4. Sedatives and Hypnotics
13.3.5. Anti-Depressants
13.3.6. Others (Antipsychotics, etc.)
13.4. Market Value Forecast, by Disease Type, 2020-2034.
13.4.1. Neurodegenerative Disorders
13.4.1.1. Alzheimer’s Disease
13.4.1.2. Parkinson’s Disease
13.4.1.3. Huntington’s Disease
13.4.1.4. Amyotrophic Lateral Sclerosis
13.4.1.5. Others (Multiple Sclerosis, etc.)
13.4.2. Mental Health
13.4.2.1. Anxiety Disorders
13.4.2.2. Epilepsy
13.4.2.3. Psychotic Disorders
13.4.2.4. Others (Mood Disorders, etc.)
13.4.3. Neurovascular Diseases
13.4.4. CNS Trauma
13.4.5. CNS Cancer
13.4.6. Others (Infectious Disorders, etc.)
13.5. Market Value Forecast, by Distribution Channel, 2020-2034.
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Distribution Channel, 2020-2034.
13.6.1. Hospitals
13.6.2. Biopharmaceutical Companies
13.6.3. Research Organizations and Academic Institutes
13.7. Market Value Forecast, by Country/Sub-region, 2020-2034
13.7.1. Brazil
13.7.2. Mexico
13.7.3. Rest of Latin America
13.8. Market Attractiveness Analysis
13.8.1. By Drug Class
13.8.2. By Disease Type
13.8.3. By Distribution Channel
13.8.4. By Country/Sub-region
14. Middle East & Africa Central Nervous System (CNS) Therapeutics Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2020-2034
14.3.1. Analgesics
14.3.2. Anti-Cholinergic Agents
14.3.3. Anticonvulsants
14.3.4. Sedatives and Hypnotics
14.3.5. Anti-Depressants
14.3.6. Others (Antipsychotics, etc.)
14.4. Market Value Forecast, by Disease Type, 2020-2034.
14.4.1. Neurodegenerative Disorders
14.4.1.1. Alzheimer’s Disease
14.4.1.2. Parkinson’s Disease
14.4.1.3. Huntington’s Disease
14.4.1.4. Amyotrophic Lateral Sclerosis
14.4.1.5. Others (Multiple Sclerosis, etc.)
14.4.2. Mental Health
14.4.2.1. Anxiety Disorders
14.4.2.2. Epilepsy
14.4.2.3. Psychotic Disorders
14.4.2.4. Others (Mood Disorders, etc.)
14.4.3. Neurovascular Diseases
14.4.4. CNS Trauma
14.4.5. CNS Cancer
14.4.6. Others (Infectious Disorders, etc.)
14.5. Market Value Forecast, by Distribution Channel, 2020-2034.
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Distribution Channel, 2020-2034.
14.6.1. Hospitals
14.6.2. Biopharmaceutical Companies
14.6.3. Research Organizations and Academic Institutes
14.7. Market Value Forecast, by Country/Sub-region, 2020-2034
14.7.1. GCC Countries
14.7.2. South Africa
14.7.3. Rest of Middle East & Africa
14.8. Market Attractiveness Analysis
14.8.1. By Drug Class
14.8.2. By Disease Type
14.8.3. By Distribution Channel
14.8.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Biogen
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Otsuka Pharmaceutical Co., Ltd.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Eli Lilly and Company
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Merck & Co. Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. AstraZeneca
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Novartis AG
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Teva Pharmaceutical Industries Ltd.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Pfizer Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Takeda Pharmaceuticals
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Johnson & Johnson Services, Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 02: Global Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
Table 03: Global Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 04: Global Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 05: North America Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 06: North America Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 07: North America Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
Table 08: North America Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 09: Europe Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 11: Europe Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
Table 12: Europe Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 13: Asia Pacific Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 15: Asia Pacific Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
Table 16: Asia Pacific Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 17: Latin America Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 19: Latin America Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
Table 20: Latin America Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 21: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 23: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
Table 24: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
List of Figures
Figure 01: Global Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) and Distribution (%), by Region, 2023. and 2034
Figure 02: Global Central Nervous System (CNS) Therapeutics Market Revenue (US$ Bn), by Drug Class, 2023
Figure 03: Global Central Nervous System (CNS) Therapeutics Market Value Share, by Drug Class, 2023
Figure 04: Global Central Nervous System (CNS) Therapeutics Market Revenue (US$ Bn), by Disease Type, 2023
Figure 05: Global Central Nervous System (CNS) Therapeutics Market Value Share, by Disease Type, 2023
Figure 06: Global Central Nervous System (CNS) Therapeutics Market Revenue (US$ Bn), by Distribution Channel, 2023
Figure 07: Global Central Nervous System (CNS) Therapeutics Market Value Share, by Distribution Channel, 2023
Figure 08: Global Central Nervous System (CNS) Therapeutics Market Value Share, by Region, 2023
Figure 09: Global Central Nervous System (CNS) Therapeutics Market Value (US$ Bn) Forecast, 2020-2034
Figure 10: Global Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Drug Class, 2023. and 2034
Figure 11: Global Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 12: Global Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Disease Type, 2023. and 2034
Figure 13: Global Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 14: Global Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Distribution Channel, 2023. and 2034
Figure 15: Global Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 16: Global Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Region, 2023. and 2034
Figure 17: Global Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 18: North America Central Nervous System (CNS) Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 19: North America Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Country, 2024-2034
Figure 20: North America Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Country, 2023. and 2034
Figure 21: North America Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Drug Class, 2023. and 2034
Figure 22: North America Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Disease Type, 2023. and 2034
Figure 23: North America Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Distribution Channel, 2023. and 2034
Figure 24: North America Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 25: North America Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 26: North America Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 27: Europe Central Nervous System (CNS) Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 28: Europe Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 29: Europe Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023. and 2034
Figure 30: Europe Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Drug Class, 2023. and 2034
Figure 31: Europe Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Disease Type, 2023. and 2034
Figure 32: Europe Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Distribution Channel, 2023. and 2034
Figure 33: Europe Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 34: Europe Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 35: Europe Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 36: Asia Pacific Central Nervous System (CNS) Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 37: Asia Pacific Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 38: Asia Pacific Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023. and 2034
Figure 39: Asia Pacific Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Drug Class, 2023. and 2034
Figure 40: Asia Pacific Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Disease Type, 2023. and 2034
Figure 41: Asia Pacific Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Distribution Channel, 2023. and 2034
Figure 42: Asia Pacific Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 43: Asia Pacific Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 44: Asia Pacific Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 45: Latin America Central Nervous System (CNS) Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 46: Latin America Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Latin America Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023. and 2034
Figure 48: Latin America Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Drug Class, 2023. and 2034
Figure 49: Latin America Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Disease Type, 2023. and 2034
Figure 50: Latin America Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Distribution Channel, 2023. and 2034
Figure 51: Latin America Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 52: Latin America Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 53: Latin America Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 54: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 55: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 56: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023. and 2034
Figure 57: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Drug Class, 2023. and 2034
Figure 58: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Disease Type, 2023. and 2034
Figure 59: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Distribution Channel, 2023. and 2034
Figure 60: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 61: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 62: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Central Nervous System (CNS) Therapeutics Market
